SGSH

N-sulfoglucosamine sulfohydrolase (SGSH), also known as heparan-N-sulfatase, is an enzyme that in humans is encoded by the SGSH gene. This enzyme is significant in the degradation of glycosaminoglycans (GAGs), specifically heparan sulfate, which is a crucial component of the extracellular matrix and cell surface. Mutations in the SGSH gene are associated with a rare autosomal recessive lysosomal storage disorder known as Sanfilippo syndrome type A, or Mucopolysaccharidosis type IIIA (MPS IIIA), characterized by severe central nervous system degeneration but only mild somatic manifestations.

Function

SGSH is involved in the lysosomal degradation of heparan sulfate, a process critical for cellular waste management and recycling. The enzyme cleaves sulfate groups from the N-sulfated glucosamine residues in heparan sulfate, an essential step in the degradation pathway of this glycosaminoglycan. Proper functioning of SGSH is vital for the turnover of heparan sulfate and, when impaired, leads to its accumulation within lysosomes, disrupting cellular function and leading to the pathology seen in Sanfilippo syndrome type A.

Genetics

The SGSH gene is located on the short (p) arm of chromosome 17 at position 17q25.3. Mutations in this gene result in deficient activity of the SGSH enzyme, leading to the accumulation of partially degraded glycosaminoglycans in the lysosome, a hallmark of Sanfilippo syndrome type A. Over 100 mutations in the SGSH gene have been identified, including missense mutations, nonsense mutations, and small insertions or deletions.

Clinical Significance

Sanfilippo syndrome type A, caused by mutations in the SGSH gene, is the most severe form of the Sanfilippo syndrome spectrum. It is characterized by progressive neurological deterioration, including developmental delay, severe hyperactivity, insomnia, and loss of speech and motor skills. Unlike other forms of Mucopolysaccharidosis, individuals with Sanfilippo syndrome type A typically do not exhibit significant somatic features (e.g., coarse facial features, organomegaly) but may have mild skeletal abnormalities. Diagnosis is confirmed through biochemical assays to measure SGSH enzyme activity and genetic testing for mutations in the SGSH gene.

Treatment

Currently, there is no cure for Sanfilippo syndrome type A. Treatment is primarily supportive and symptomatic, focusing on improving quality of life and managing symptoms. This may include physical therapy, occupational therapy, and speech therapy to support motor and communication skills, as well as medication to manage behavioral problems. Research into potential treatments, including enzyme replacement therapy, gene therapy, and substrate reduction therapy, is ongoing.

See Also

• Lysosomal storage disorder
• Mucopolysaccharidosis
• Glycosaminoglycan
• Enzyme replacement therapy
• Gene therapy